Reset
Showing 4 of 4 academic articles

Protocol to measure human IL-6 secretion from CAR T cell-primed macrophage and monocyte lineage cells in vitro and in vivo using humanized mice

Thao Nguyen, Toshiaki Yoshikawa, Yusuke Ito, Hitomi Kasuya et al. • STAR Protocols (2024)

Summary: Chimeric antigen receptor (CAR) T cell therapy often causes serious toxicities, such as cytokine release syndrome (CRS), mainly due to interleukin-6 (IL-6) secreted by monocyte lineage cells. Here, we describe a protocol to generat...

DOAJ Open Access (DOAJ) DOI: 10.1016/j.xpro.2024.103423

Dynamic monitoring of circulating tumor DNA reveals outcomes and genomic alterations in patients with relapsed or refractory large B-cell lymphoma undergoing CAR T-cell therapy

Wei Liu, Yan Xu, Yi Wang, Lugui Qiu et al. • Journal for ImmunoTherapy of Cancer (2024)

Background Over 50% of patients with relapsed or refractory large B-cell lymphoma (r/r LBCL) receiving CD19-targeted chimeric antigen receptor (CAR19) T-cell therapy fail to achieve durable remission. Early identification of relapse or prog...

DOAJ Open Access (DOAJ) DOI: 10.1136/jitc-2023-008450

Advances in CAR T cell therapy: antigen selection, modifications, and current trials for solid tumors

Safwaan H. Khan, Safwaan H. Khan, Yeonjoo Choi, Mysore Veena et al. • Frontiers in Immunology (2025)

Chimeric antigen receptor (CAR) T cell therapy has revolutionized the treatment of hematologic malignancies, achieving remarkable clinical success with FDA-approved therapies targeting CD19 and BCMA. However, the extension of these successe...

DOAJ Open Access (DOAJ) DOI: 10.3389/fimmu.2024.1489827